This company listing is no longer active
Calliditas Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Calliditas Therapeutics's earnings have been declining at an average annual rate of -22.5%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 59.4% per year.
Anahtar bilgiler
-22.5%
Kazanç büyüme oranı
-18.5%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 6.0% |
Gelir büyüme oranı | 59.4% |
Özkaynak getirisi | -449.8% |
Net Marj | -30.0% |
Sonraki Kazanç Güncellemesi | 11 Nov 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics
May 28Calliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64M
Aug 18Calliditas Therapeutics wins European approval for Kinpeygo for IgA nephropathy
Jul 15Calliditas submits nefecon marketing authorisation application to the EMA
May 28Calliditas shares rise 10% as FDA grants priority review for Nefecon
Apr 28Calliditas Therapeutics reports Q3 results
Nov 12Gelir ve Gider Dağılımı
Calliditas Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 1,601 | -480 | 1,314 | 558 |
31 Mar 24 | 1,311 | -525 | 1,163 | 526 |
31 Dec 23 | 1,207 | -466 | 1,061 | 502 |
30 Sep 23 | 1,184 | -451 | 1,040 | 498 |
30 Jun 23 | 1,150 | -292 | 968 | 421 |
31 Mar 23 | 944 | -393 | 872 | 428 |
31 Dec 22 | 803 | -412 | 775 | 415 |
30 Sep 22 | 405 | -628 | 653 | 413 |
30 Jun 22 | 343 | -608 | 562 | 402 |
31 Mar 22 | 279 | -576 | 474 | 381 |
31 Dec 21 | 229 | -500 | 390 | 357 |
30 Sep 21 | 199 | -452 | 302 | 331 |
30 Jun 21 | 0 | -600 | 248 | 304 |
31 Mar 21 | 0 | -501 | 182 | 277 |
31 Dec 20 | 1 | -433 | 142 | 241 |
30 Sep 20 | 47 | -286 | 102 | 209 |
30 Jun 20 | 47 | -198 | 71 | 190 |
31 Mar 20 | 185 | -54 | 71 | 173 |
31 Dec 19 | 185 | -33 | 63 | 150 |
30 Sep 19 | 138 | -54 | 47 | 142 |
30 Jun 19 | 138 | -35 | 44 | 120 |
31 Mar 19 | 0 | -136 | 33 | 99 |
31 Dec 18 | 0 | -132 | 31 | 99 |
30 Sep 18 | 0 | -128 | 64 | 65 |
30 Jun 18 | 0 | -115 | 74 | 41 |
31 Mar 18 | 0 | -113 | 81 | 31 |
31 Dec 17 | 0 | -87 | 85 | 0 |
31 Dec 16 | 0 | -57 | 56 | 0 |
Kaliteli Kazançlar: CALT is currently unprofitable.
Büyüyen Kar Marjı: CALT is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: CALT is unprofitable, and losses have increased over the past 5 years at a rate of 22.5% per year.
Büyüme Hızlandırma: Unable to compare CALT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: CALT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Özkaynak Getirisi
Yüksek ROE: CALT has a negative Return on Equity (-449.83%), as it is currently unprofitable.